Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03488238 · ClinicalTrials.gov registry record
Correlation of Changes in PaO2 and ORi in Adult Patients
A clinical trial, sponsored by Masimo Corporation.
- Completed
- Registry status
- 31
- Enrollment target
NCT03488238: Completed study, sponsored by Masimo Corporation.
NCT03488238 is a clinical trial that has completed, run by Masimo Corporation. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03488238 has completed, sponsored by Masimo Corporation.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00. An ORi of 0.00 corresponds to PaO2 values of 100mmHg and below and an ORi of 1.00 corresponds to PaO2 values of 200mmHg and above. This is a prospective, non-blinded, non-randomized study of the Oxygen Reserve Index (ORi) in a clinical setting. It is designed to evaluate the correlations with ORi and changes in PaO2 and the potential use of ORi as an early warning of impending arterial oxygen desaturation.
Primary Outcome
ORi is an index value without a unit and ORi does not directly measure PaO2. Therefore, sensitivity is calculated to evaluate changes in ORi relative to the changes in PaO2.
Interventions
- DEVICE ORi sensor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2018-09-19 |
What the finished NCT03488238 record still lists
NCT03488238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ORi sensor is the first listed.
NCT03488238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03488238 about?
NCT03488238 is a clinical study titled "Correlation of Changes in PaO2 and ORi in Adult Patients". The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00. An ORi of 0.00 corresponds to PaO2 values of 100mmHg and below and an ORi of 1.00 corresponds to PaO2...
What is the current status of trial NCT03488238?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2018-08-01. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT03488238?
The interventions under investigation include: ORi sensor (DEVICE).
Who is sponsoring clinical trial NCT03488238?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI